- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03836716
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- Catholic University Leuven
-
-
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre
-
-
-
-
-
Montpellier, France, 34295
- Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac
-
Paris, France, 75013
- Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422
-
-
-
-
-
Berlin, Germany, 13353
- Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie
-
Ulm, Germany, 89081
- Universitaetsklinikum Ulm - Klinik fuer Neurologie
-
-
-
-
-
Milano, Italy, 20138
- Instituti Clinica Scientifici Maugeri
-
Torino, Italy, 10126
- Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino
-
-
-
-
-
Utrecht, Netherlands, 3584CX
- University Medical Center Utrecht
-
-
-
-
-
Warsaw, Poland, 01-684
- Centrum Medyczne NeuroProtect
-
Warsaw, Poland, 02-473
- Citi Clinic
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11
-
Madrid, Spain, 28046
- Hospital Carlos III - Hospital Universitario La Paz, ALS Unit
-
-
-
-
-
Umeå, Sweden, 90737
- Umeå University Hospital
-
-
-
-
-
London, United Kingdom, WC1N 3BG
- Leonard Wolfson Experimental Neurology Centre
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center
-
-
California
-
Orange, California, United States, 92868
- UC Irvine Health ALS and Neuromuscular Center
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Brain & Spine Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is able to comprehend and is willing to provide written informed consent and is capable and willing to comply with trial procedures, or in the circumstance that the subject is incompetent, informed consent/assent is provided in accordance with local regulation and/or procedures
- Subject has completed the ORARIALS-01 trial (i.e., met one of the surrogate survival endpoints of tracheostomy or PAV or has completed the 76 weeks randomized treatment period)
- Subject completed ORARIALS-01 while on treatment, where on treatment is defined as having taken the last dose of IMP within 2 weeks of the End of Trial visit (whether at week 76 or prior)
Exclusion Criteria:
- Known or suspected allergy or intolerance to the IMP (Arimoclomol or constituents)
- Exposure to any other investigational treatment, advanced therapy medicinal product or use of any other prohibited concomitant medications
- Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of birth control if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for female participants until 4 weeks after last dose and for male participants until 3 months after last dose. Pre-menopausal women must have a negative pregnancy test prior to dosing with trial medication.
Any of the following medically significant conditions:
- Clinically significant renal or hepatic disease OR clinical laboratory assessment (results ≥ 3 times the upper limit of normal [ULN] for aspartate aminotransferase and/or alanine aminotransferase, bilirubin ≥ 2 times the ULN, or creatinine ≥ 1.5 times the ULN).
- Any new condition or worsening of existing condition which, in the opinion of the investigator, would put the subject at undue risk.
- Any serious adverse event or moderate/severe adverse event from the ORARIALS-01 trial which is ongoing at the time of transitioning to ORARIALS-02 and assessed as probably related to IMP
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arimoclomol
248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
|
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Open-label Treatment Period
Time Frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
|
Adverse event (AE) data were collected throughout the trial until early termination. The average duration of exposure was 198.7 days (approximately 28 weeks; standard deviation 99.57 days; minimum 16 days, maximum 494 days). 58 participants (48.3%) were exposed less than 6 months; 55 participants (45.8%) were exposed 6 to less than 12 months; 7 participants (5.8%) were exposed 12 to less than 18 months. No participant was treated for 76 weeks. Participants with on-treatment TEAEs are reported. An on-treatment TEAE is any TEAE in the on-treatment period defined as the time from first dose of IMP until 14 days since the last preceding administration of IMP (either before a temporary IMP interruption with duration >14 days or the last dose at the end of trial). A participant may have several on-treatment periods separated by interruption intervals. |
From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematology (1)
Time Frame: Week 76
|
Standard hematology parameters.
White blood cell differential count for basophils, eosinophils, leukocytes, lymphocytes, monocytes, and neutrophils, and platelet count.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematology (2)
Time Frame: Week 76
|
Standard hematology parameters.
Percentage of leukocytes were determined for basophils, eosinophils, lymphocytes, monocytes, and neutrophils
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Erythrocytes
Time Frame: Week 76
|
Standard hematology parameter.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematocrit
Time Frame: Week 76
|
Standard hematology parameter.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hemoglobin
Time Frame: Week 76
|
Standard hematology parameter.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (1)
Time Frame: Week 76
|
Standard clinical chemistry parameters.
Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (2)
Time Frame: Week 76
|
Standard clinical chemistry parameters.
Calcium, Calcium Corrected, Cholesterol, Glucose, HDL Cholesterol, LDL Cholesterol, Potassium, Sodium, Triglycerides, and Urea Nitrogen.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (3)
Time Frame: Week 76
|
Standard clinical chemistry parameters.
Bilirubin, Creatinine, Direct Bilirubin, and Indirect Bilirubin.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Albumin and Protein
Time Frame: Week 76
|
Standard clinical chemistry parameters.
|
Week 76
|
Mean and Change From Baseline in Clinical Safety Laboratory Tests - Cystatin C
Time Frame: Week 76
|
Standard clinical chemistry parameter.
|
Week 76
|
Mean and Change From Baseline in Vital Signs - Blood Pressure
Time Frame: Week 76
|
Standard vital signs.
Systolic and diastolic blood pressure.
|
Week 76
|
Mean and Change From Baseline in Vital Signs - Pulse Rate
Time Frame: Week 76
|
Standard vital signs measurement.
|
Week 76
|
Mean and Change From Baseline in Vital Signs - Respiratory Rate
Time Frame: Week 76
|
Standard vital signs measurement.
|
Week 76
|
Mean and Change From Baseline in Vital Signs - Temperature
Time Frame: Week 76
|
Standard vital signs measurement.
|
Week 76
|
Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Safety Laboratory Tests and Vital Signs Over the Open-label Treatment Period
Time Frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
|
Clinical safety laboratory data and vital signs were collected throughout the trial until early termination.
The average duration of exposure was 198.7 days (approximately 28 weeks; standard deviation 99.57
days; minimum 16 days, maximum 494 days).
58 participants (48.3%) were exposed less than 6 months; 55 participants (45.8%) were exposed 6 to less than 12 months; 7 participants (5.8%) were exposed 12 to less than 18 months.
No patient was treated for 76 weeks.
|
From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
|
Columbia-Suicide Severity Rating Scale (C-SSRS) Over the Open-label Treatment Period
Time Frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
|
The C-SSRS is a detailed questionnaire assessing both suicidal behavior and suicidal ideation through a series of simple, plain-language questions administered as an interview by a qualified investigator or delegate.
|
From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in ALS Functional Rating Scale - Revised (ALSFRS-R) From Baseline to Week 76
Time Frame: Week 76
|
The ALSFRS-R is an ordinal rating scale used to determine subjects' subjective assessment of their capability and independence with 12 functional activities ('speech', 'salivation', 'swallowing', handwriting', 'cutting food and handling utensils', 'dressing and hygiene', 'turning in bed and adjusting bed clothes', 'walking', 'dyspnoea', 'orthopnoea' and 'respiratory insufficiency').
Each activity is rated on a 5-point scale (from 0 [no ability] to 4 [normal]), giving a maximal ALSFRS-R score of 48.
A lower score corresponds to a lower capability and independence.
|
Week 76
|
Change in Percentage (%) Predicted Slow Vital Capacity (SVC) From Baseline to Week 76 (for Subjects Who Did Not Meet the Survival Endpoint in the ORARIALS-01 Trial)
Time Frame: 76 weeks
|
Slow vital capacity (SVC) measures the volume that can be exhaled from a full inhalation after exhaling to a maximum as slowly as possible. Predicted SVC was derived per European Community of Coal and Steel (ECCS) reference equations:
|
76 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Benatar, MD PhD, University of Miami
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORARIALS-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Arimoclomol
-
CytRxCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Richard Barohn, MDCompletedInclusion Body MyositisUnited States, United Kingdom
-
University of MiamiMassachusetts General HospitalCompletedAmyotrophic Lateral SclerosisUnited States
-
CytRxWithdrawnAmyotrophic Lateral SclerosisUnited States, Canada
-
ZevraDenmarkAvailableNiemann-Pick Disease, Type CUnited States
-
KemPharm Denmark A/STerminatedGaucher Disease, Type 1 | Gaucher Disease, Type 3India
-
ZevraDenmarkUniversity College, London; University of Kansas Medical CenterTerminatedInclusion Body MyositisUnited States, United Kingdom
-
ZevraDenmarkCompletedAmyotrophic Lateral SclerosisCanada, United States, Belgium, Netherlands, Poland, United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland
-
ZevraDenmarkActive, not recruitingNiemann-Pick Disease, Type CUnited States, Spain, United Kingdom, Denmark, France, Germany, Italy, Poland, Switzerland
-
ZevraDenmarkUniversity College, London; University of Kansas Medical CenterCompletedInclusion Body MyositisUnited States, United Kingdom